William Blair

Canaccord and William Blair also increased their price targets on  Quidel's shares, following its acquisition of certain Alere assets and assays.

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

In upgrading PacBio's shares to Outperform, the investment bank also took note of potential new revenues from its Roche deal and possibly a new platform launch next year.

The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.

Cowen & Co. upgraded Fluidigm to an Outperform rating, while William Blair upgraded Hologic also to Outperform. 

NEW YORK (GenomeWeb) – Investment bank William Blair today upgraded its rating for Sequenom's shares to Outperform on expectations of continued adoption of the molecular diagnostic firm's non-invasive prenatal testing technology and recent business developments that could increase revenues.

NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded Pacific Biosciences to a Neutral rating after the next-generation sequencing company announced better than expected placements of its instruments.

NEW YORK (GenomeWeb News) — William Blair today downgraded Sequenom after the San Diego-based company firm missed Wall Street estimates on the top and bottom lines in its second quarter.

NEW YORK (GenomeWeb News) – William Blair on Thursday initiated coverage of Waters, saying it believes the company can continue on its path of revenue growth and noting Waters consumables business and emerging market presence.

NEW YORK (GenomeWeb News) – Following a spike in Life Technologies' share price after a report that the company may be searching for a buyer, investment firm William Blair today downgra

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.